Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.57 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | SORD | Q00796 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 4/20 | 0.40 |
| ▸ | CNR2 | P34972 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | LDHA | P00338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL788586 | 0.92 | PIK3CD (0.57) | PIK3CDPIK3R1SMN1; SMN2SORDCNR1 | |
| SCHEMBL18175791 | 0.79 | PIK3CD (0.63) | PIK3CDPIK3R1CNR1CNR2POLB | |
| SCHEMBL806202 | 0.79 | PIK3CD (0.66) | PIK3CDPIK3R1SMN1; SMN2CNR1CNR2 | |
| SCHEMBL787665 | 0.77 | PIK3CD (0.61) | PIK3CDPIK3R1SMN1; SMN2CNR1CNR2 | |
| SCHEMBL788012 | 0.77 | PIK3CD (0.63) | PIK3CDPIK3R1CNR1CNR2RXFP1 | |
| SCHEMBL795508 | 0.76 | PIK3CD (0.58) | PIK3CDPIK3R1CNR1CNR2 | |
| SCHEMBL806325 | 0.76 | PIK3CD (0.58) | PIK3CDPIK3R1CNR1CNR2 | |
| SCHEMBL793688 | 0.76 | PIK3CD (0.65) | PIK3CDPIK3R1ALDH1A1POLB | |
| SCHEMBL806116 | 0.76 | PIK3CD (0.60) | PIK3CDPIK3R1CNR1CNR2 | |
| SCHEMBL798997 | 0.76 | PIK3CD (0.61) | PIK3CDPIK3R1CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616469-B1 | 9H-PURINE COMPOUNDS AS PI3K-DELTA INHIBITORS AND METHODS FOR THEIR MANUFACTURE | EXELIXIS INC (US) | 2016-10-26 | — | — | EP | claimed |
| US-9346807-B2 | Inhibitors of PI3K-delta and methods of their use and manufacture | EXELIXIS, INC. (US) | 2016-05-24 | — | — | US | claimed |
| US-20140058103-A1 | Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-02-27 | — | — | US | claimed |
| EP-2616469-A1 | INHIBITORS OF PI3K-DELTA AND METHODS OF THEIR USE AND MANUFACTURE | Exelixis, Inc. (US) | 2013-07-24 | — | — | EP | claimed |
| EP-2607371-A1 | Processes for the preparation of abiraterone and related compouds | Crystal Pharma, S.A.U. (ES) | 2013-06-26 | — | — | EP | claimed |
| US-8313978-B2 | Organic semiconductor copolymers containing oligothiophene and n-type heteroaromatic units | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2012-11-20 | — | — | US | claimed |
| WO-2012037226-A1 | INHIBITORS OF PI3K-DELTA AND METHODS OF THEIR USE AND MANUFACTURE | EXELIXIS, INC. (US) | 2012-03-22 | — | — | WO | claimed |
| US-20080224130-A1 | ORGANIC SEMICONDUCTOR COPOLYMERS CONTAINING OLIGOTHIOPHENE AND n-TYPE HETEROAROMATIC UNITS | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2008-09-18 | — | — | US | claimed |
| US-20060006379-A1 | Organic semiconductor copolymers containing oligothiophene and n-type heteroaromatic units | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2006-01-12 | — | — | US | claimed |
| EP-1615237-A1 | Organic semiconductor copolymers containing oligothiophene and n-type heteroaromatic units | Samsung Electronics Co., Ltd (KR) | 2006-01-11 | — | — | EP | claimed |
| US-12492180-B2 | Process and intermediates for the preparation of Voxelotor | CURIA SPAIN, S.A.U. (ES) | 2025-12-09 | — | — | US | disclosed |
| US-20220073493-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF VOXELOTOR | CURIA SPAIN, S.A.U. (ES) | 2022-03-10 | — | — | US | disclosed |
| US-9879025-B2 | Transfer hydrogenation of cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170029433-A1 | TRANSFER HYDROGENATION OF CYCLOPAMINE ANALOGS | ROYALTY SECURITY, LLC | 2017-02-02 | — | — | US | disclosed |
| EP-2616469-B1 | 9H-PURINE COMPOUNDS AS PI3K-DELTA INHIBITORS AND METHODS FOR THEIR MANUFACTURE | EXELIXIS INC (US) | 2016-10-26 | — | — | EP | disclosed |
| EP-2616469-A1 | INHIBITORS OF PI3K-DELTA AND METHODS OF THEIR USE AND MANUFACTURE | Exelixis, Inc. (US) | 2013-07-24 | — | — | EP | disclosed |
| EP-2607371-A1 | Processes for the preparation of abiraterone and related compouds | Crystal Pharma, S.A.U. (ES) | 2013-06-26 | — | — | EP | disclosed |
| WO-2012037217-A1 | TRANSFER HYDROGENATION OF CYCLOPAMINE ANALOGS | INFINITY PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012037226-A1 | INHIBITORS OF PI3K-DELTA AND METHODS OF THEIR USE AND MANUFACTURE | EXELIXIS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012037226-A1 | INHIBITORS OF PI3K-DELTA AND METHODS OF THEIR USE AND MANUFACTURE | EXELIXIS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140058103-A1 | Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture | PIK3CD, PIK3CA, PIK3R5 | PIK3CD 1/4885PIK3R1 6/4885SMN1; SMN2 3939/4885 |
| US-20220073493-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF VOXELOTOR | VPS51, KIF15, VAT1 | PIK3CD 1139/4885PIK3R1 2063/4885SMN1; SMN2 229/4885 |
| US-20170029433-A1 | TRANSFER HYDROGENATION OF CYCLOPAMINE ANALOGS | HVCN1, KCNQ4, KCNQ5 | PIK3CD 3057/4885PIK3R1 4756/4885SMN1; SMN2 4225/4885 |
| US-12492180-B2 | Process and intermediates for the preparation of Voxelotor | VPS51, KIF15, VAT1 | PIK3CD 1139/4885PIK3R1 2063/4885SMN1; SMN2 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.